Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;23(1):61-67.
doi: 10.1007/s40257-021-00646-z. Epub 2021 Dec 2.

Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians

Sonal Muzumdar  1 , Lauren Skudalski  2   3 , Kelley Sharp  4 , Reid A Waldman  5
Affiliations
Review

Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians

Sonal Muzumdar et al. Am J Clin Dermatol. 2022 Jan.

Abstract

Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults. Aside from reviewing the pathogenesis and clinical presentation, we present potential diagnostic steps (such as skin scraping, serologies, biopsy, and patch testing) and management options for DFR ranging from allergen avoidance to dupilumab interruption. It is hoped that this article will serve as a means for clinicians to familiarize themselves with DFR regarding the differential diagnosis, diagnostic tools, and treatment options associated with this phenomenon.

PubMed Disclaimer

References

    1. Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update (review). Experimental and Therapeutic Medicine [Internet]. Spandidos Publications; 2019 [cited 2021 Apr 17];17:1061–7. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/30679974/ .
    1. Gooderham MJ, Hong HC ho, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2018 [cited 2021 Apr 17];78:S28–36. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/29471919/ .
    1. Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 Submissions to the US FDA’s Office of Clinical Pharmacology. Journal of Clinical Pharmacology [Internet]. Blackwell Publishing Inc.; 2020 [cited 2021 Apr 17];60:S160–78. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/33205429/ .
    1. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2020 [cited 2021 Apr 17];82:377–88. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31374300/ .
    1. Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatology [Internet]. American Medical Association; 2020 [cited 2021 Apr 17];156:131–43. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31876900/ .

MeSH terms

LinkOut - more resources